Skip to content

Kete Campbell‐coker

6 papers in the library · 1,115 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

Nature Medicine August 6, 2026 James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al. 1 citation

Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol

Wellcome Open Research April 22, 2025 Matthew Butler, Catherine Bird, Carolina Maggio et al. 3 citations

Background Functional neurological disorder (FND) is a common cause of neurological symptoms including seizures and movement disorders. It can be debilitating, is associated with high health and social care costs, and can have a poor prognosis. Functional magnetic resonance imaging (fMRI) has suggested FND is a multi-network disorder. Converging evidence suggests that other mechanisms including...

Plain Language Summary Publication: Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: Results from an open‐label phase Ib ascending dose study

Headache The Journal of Head and Face Pain October 9, 2024 James Rucker, Matthew Butler, Sadie Hambleton et al.

Matt Butler has nothing to declare. Sanjay Cheema: Received a research fellowship sponsored by Abbott. Giorgio Lambru: Co-chair of the Medical Advisory Board of the Trigeminal neuralgia Association (TNA) UK; received personal fees from Abbvie, Teva, Novartis, Eli Lilly, Lundbeck; participated in clinical trials as principal investigator for Novartis, Eli Lilly, Teva, Nevro. Manjit Matharu:...

Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: results from an open‐label phase Ib ascending dose study

Headache The Journal of Head and Face Pain September 20, 2024 James Rucker, Sadie Hambleton, Catherine Bird et al. 12 citations

Abstract Background Short‐lasting unilateral neuralgiform headache attacks (SUNHA) are trigeminal autonomic cephalalgias that feature intense and recurrent paroxysms of pain and autonomic symptoms. Many patients are left with debilitating symptoms despite best‐available treatment. Psychedelics, such as the serotonin 2A partial agonist psilocybin, have shown promise in related disorders such as...

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.

Wellcome Open Research 2024 Matt Butler, Catherine Bird, Carolina Maggio et al. 4 citations

Functional neurological disorder (FND) is a common cause of neurological symptoms including seizures and movement disorders. It can be debilitating, is associated with high health and social care costs, and can have a poor prognosis. Functional magnetic resonance imaging (fMRI) has suggested FND is a multi-network disorder. Converging evidence suggests that other mechanisms including...

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

The New England journal of medicine November 3, 2022 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 1,095 citations

Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...